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Photodynamic therapy (PDT), a treatment for cancer, uses a photo-
sensitizer and laser irradiation to produce reactive oxygen in cells. In
Japan, the United States, and many other countries, PDT is a
treatment option for stage 0 (TisN0M0) and stage I (T1N0M0)
centrally located early stage lung cancer. PDT can preserve lung
function, can be repeated, and can be combined with other thera-
peutic modalities such as chemotherapy. Recently, mono-L-aspartyl
chlorine e6 (NPe6, Laserphyrin), a second-generation photosensi-
tizer with lower photosensitivity than Photofrin (porfimer sodium),
was approved by the Japanese government and a phase II clinical
study using NPe6 with a new diode laser demonstrated an excellent
antitumor effect and low skin photosensitivity. We expect PDT to be
widely employed in many fields and the applications of PDT to be
extended because of the decreasing cost of laser equipment and
lower systemic photosensitivity induced by the photosensitizer. The
purpose of this review is to introduce not only recent clinical trials
of PDT for centrally located early lung cancer, but also new
applications of PDT for cases of peripheral-type, early-stage lung
cancers. We also discuss the applications of PDT for advanced lung
cancer and combined therapy using PDT and other treatments for
lung cancer.
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INTRODUCTION TO PHOTODYNAMIC
THERAPY AND CELL DEATH
Photodynamic therapy (PDT) is a novel treatment for
cancer and certain noncancerous conditions that are generally
characterized by proliferation of unwanted or malignant
cells.1,2 The procedure requires exposure of cells and tissues
to a photosensitizing drug followed by irradiation with visible
light of appropriate wavelength, usually in the red or near-
infared region and compatible with the absorption spectrum
of the photosensitizer drug. Upon absorption of a photon, the
photosensitizer undergoes one or more energy transitions and
usually emerges in its excited triplet state. The triplet can
participate in a one-electron oxidation-reduction reaction
(type I photochemistry) with a neighboring molecule, pro-
ducing free radical intermediates that can react with oxygen
to produce peroxyradicals and various reactive oxygen spe-
cies (ROS).3,4 Alternatively, the triplet-state photosensitizer
can transfer energy to ground state oxygen (type II photo-
chemistry), generating singlet molecular oxygen, a highly
reactive form of oxygen that reacts with many biological
molecules, including lipids, proteins, and nucleic acids. The
photosensitizers for PDT are primarily porphyrins or porphy-
rin-related derivatives with hydrophobic aromatic ring struc-
tures, and they localize in one or more cellular membranes.5
Most photosensitizers do not accumulate in cell nuclei, and
the potential of PDT to cause DNA damage, mutations, and
carcinogenesis is low. The photosensitizer Photofrin (por-
fimer sodium) preferentially binds to mitochondrial mem-
branes, endoplasmic reticulum, and Golgi complexes in can-
cer cells. Singlet oxygen species and other ROS that are
produced by PDT in the membranes cause photo-oxidative
damage to proteins and lipids that reside within a few nano-
meters of the photosensitizer binding sites. PDT rapidly
induces apoptosis, inflammatory reaction, tumor-specific
and/or -nonspecific immune reaction and damages the micro-
vasculature of the tumor bed.2,6–9 With some photosensitiz-
ers, the effect on the vasculature is the most important
mechanism of their therapeutic effect.
BACKGROUND
In 1978, Dougherty et al.1 reported the first clinical case
of PDT in a patient with metastatic breast cancer to the skin,
and in 1978 we began our study of PDT and photodynamic
diagnosis using hematoporphyrin derivative and a krypton
ion laser or argon dye laser.10,11 In 1980, we performed the
first endoscopic PDT procedure for human lung cancer in a
patient with poor cardiopulmonary function in whom surgery
was not possible. This was an advanced squamous cell
carcinoma obstructing the right main bronchus, resulted in
opening of the bronchus by PDT. The second case was an
early stage squamous cell carcinoma of the right upper
bronchus in March of 1980.12,13 The patient was a 74-year-
old man who refused surgery, and this became the first case
in the world in which PDT was performed for an early-stage
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lung cancer. A complete cure was obtained, and he remained
disease free for 5 years.14
PHOTOSENSITIZER
For lung cancer patients, two kinds of photosensitizers
are used. The most common is Photofrin (porfimer sodium).
The first health agency approval of PDT with Photofrin was
obtained in Canada in 1993 for the treatment of bladder
cancer. Subsequently, approval of Photofrin was obtained in
The Netherlands and France for the treatment of advanced
lung cancers, in Germany for the treatment of early stage lung
cancer, and Japan for early-stage lung cancer. Currently,
approvals are being sought in 10 additional countries in
Europe.1
The major side effect of Photofrin itself is skin photo-
sensitivity, which can last as long aso 4 to 6 weeks.1,2,15
Photofrin remains in cancer cells longer than in normal cells,
thus providing some tissue selectivity. When the cancer cells
are exposed to 630-nm red light, Photofrin absorbs the light
and in the presence of oxygen for toxic radicals.
Phase II clinical trials using Photofrin for early-stage
lung cancer were conducted from June of 1989 to March of
1992.15 The Japanese government approved PDT using Pho-
tofrin in October of 1994, and authorized reimbursement
through the National Health Insurance began in April of
1996.16
In 1995, the U.S. Food and Drug Administration (FDA)
approved Photofrin for esophageal cancer, and in 1998, it was
approved for the treatment of early non-small cell lung
cancer.1,16
The other photosensitizer used for lung cancer, is
mono-L-aspartyl chlorine e6 (talaporfin sodium, Laserphyrin,
NPe6), which was approved by the Japanese government in
2003.16 Laserphyrin, another effective photosensitize has a
major absorption band at 664 nm and with a molecular weight
of 799.69. A phase I clinical study using NPe6 suggested that
the optimal conditions in terms of safety and efficacy were
intravenous administration of 40 mg/m2 and laser irradiation
at 4 hours after administration.17 A phase II clinical study
demonstrated excellent antitumor effects and safety, includ-
ing lower skin photosensitivity, compared with Photofrin.18
LASER EQUIPMENT AND PROCEDURE
In Photofrin PDT, we use either an excimer dye laser
(EDL) system, which was developed by the authors and
Hamamatsu Photonics Inc. (Shizuoka, Japan), or a YAG-
OPO (Ishikawajima Harima Industry Co., Ltd., Tokyo, Ja-
pan) laser system. These 630-nm wavelength light beams are
transmitted via a quartz fiber inserted through the instrumen-
tation channel of the channel of a fiber-optic bronchoscope.
In the EDL system, the frequency was 20 to 60 Hz, and the
energy was adjusted to a 4 mJ/pulse. The illumination time
generally ranged from 10 to 40 minutes, giving energy
densities of 100 to 800 J/cm2. Outside Japan, a diode laser is
currently used for activation of Photofrin.
For Laserphyrin PDT, we use an aluminum gallium
indium phosphorus (AlGaInP) diode laser system (Panalas
6405, Matsushita Electric Industrial Co., Ltd., Osaka, Ja-
pan).17,18 The laser wavelength is adjusted to 664 nm, and the
power output can be varied from 50 to 500 mW at the fiber
tip in a continuous wave mode. The laser system weighs 20
kg and is portable.17,18
CRITERIA OF EARLY-STAGE LUNG CANCER
In Japan, the criteria of early-stage lung cancer were
strictly defined in 1975.16 Early-stage lung cancer should be
divided into two categories: central type or peripheral type,
according to the site of origin. In the central type early-stage
lung cancer, most patients have symptoms such as cough,
sputum production, or blood-tinged sputum. The tumor must
be located only as far as the segmental bronchi and be
carcinoma in situ or with only limited invasion into the
bronchial wall. The histologic type should be squamous cell
carcinoma. In the peripheral type, the tumor should be located
in the subsegmental or more peripheral bronchi, 2 cm in
diameter, and without evidence of metastasis.
PDT FOR CENTRALLY LOCATED EARLY-STAGE
LUNG CANCER
In the United States, the National Cancer Institute has
recommended PDT as a treatment option for stage 0
(TisN0M0) and stage I (T1N0M0) centrally located early-
stage lung cancer.1
In 1997, Cortese et al.19 reported on a group of 21
patients with 23 centrally located early-stage lung cancers.
These patients received 200 to 400 J/cm2 of 630 nm irradia-
tion after injection of hematoporphyrin derivative. Fifteen
patients showed a complete response (CR) after PDT. A CR
lasting longer than 12 months was noted in 11 patients (52%).
They concluded that PDT may be an alternative to surgery for
patients with early-stage squamous cell carcinoma.19
In 1988, a multicenter study on PDT for centrally
located early-stage lung cancer was performed by the PDT
cancer group of the Japanese Ministry of Health, Labor, and
Welfare.20 This study demonstrated a CR rate of 77.3% (51 of
66 lesions), and for cases with lesions1 cm in diameter, the
CR rate was 100% (28 lesions), and the overall recurrence
was 15.7 % (eight of 51 lesions).
A prospective phase II study on PDT with Photofrin for
centrally located early-stage lung cancer was conducted using
either an argon dye laser or EDL from June of 1989 to
February of 1992 in Japan.15,16 In the study, 54 patients with
64 early-stage lung cancers were treated using Photofrin (2.0
mg/kg) and 630-nm illumination of 100 to 200 J/cm2. Of 59
assessable cancers, 50 were shown to have a CR (84.8%), six
had partial response, and three had no response.
While the effectiveness of PDT using Photofrin has
been recognized clinically, it is not widely employed. This is
due in part to the cost of the laser equipment and the problems
posed by the skin photosensitization.16 Many investigators
have shown interest in the synthesis of new photosensitizers
that possess lower skin photosensitivity for use in PDT.21,22
From April of 1995 to December of 1996, we per-
formed a phase I clinical study of centrally located early-
stage lung cancer using Laserphyrin. This second-generation
photosensitizer has low photosensitivity and uses a small
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diode laser. The results were analyzed in eight eligible pa-
tients, and CR was obtained in 87.5%. A phase II clinical
study was then conducted to investigate antitumor effects and
the safety of Laserphyrin and the diode laser.18 A total of 10
institutions participated in this study from October of 1997 to
March of 2000. Laser irradiation (100 J/cm2) using a diode
laser was performed 4 hours after administration of Laser-
phyrin (40 mg/m2). Among 41 patients with 46 lesions, 40
with 45 lesions were eligible for efficacy evaluation. Disap-
pearance of skin photosensitivity was reported within 2
weeks in 28 of 33 patients (84.8%) and in the other seven
patients first tested at 15 to 18 days. CR was obtained in
84.6% of lesions (82.9% patients).
In 2002, therapeutic guidelines for lung cancer were
established by the Japanese Ministry of Health, Labor, and
Welfare using the principles of evidence-based medicine.16
PDT was recommended as a treatment option for centrally
located early-stage lung cancer. Our criteria for the treatment
of centrally located early-stage lung cancer using PDT are (1)
patients with endoscopically assessable early-stage lung can-
cer, (2) patients with normal chest x-ray and computed
tomography scan, (3) no metastasis to lymph nodes and no
distant metastasis revealed by routine clinical diagnostic
methods (N0M0), (4) tumor size not 1 cm in greatest
diameter.
One can see the important correlation between response
rate and tumor size based on better staging methods. For PDT
to be successful, it is necessary that tumor growth is limited
to the mucosa and submucosa. It has been reported that the
depth of tumor invasion as estimated by surface diameter was
not always accurate when histopathologic specimens were
examined and that some tumors 1.0 cm may show extra-
cartilaginous invasion.16 Usuda et al.23 reported that tumor
invasion in layers of bronchial wall deeper than 3 mm may
already have tumor spread to regional lymph nodes. To
evaluate the depth of tumor is very important for excluding
N1 disease. Furukawa et al.24 reported that the CR rate was
92.8% for lesions 1.0 cm in diameter and 58.1% for lesions
1.0 cm. Recurrence after CR was observed in nine of 77
lesions (11.7%). The recurrent lesions were treated with a
repeat course of PDT in seven patients and an operation in
two patients. The overall 5-year survival rate was 57.9%,
reflecting the advanced age and comorbidities of this group.
Table 1 summarizes the clinical trials done for PDT.
We now can clearly determine the tumor margin using
autofluorescence endoscopy, but it is still difficult to evaluate
this using conventional bronchoscopy. Improving the assess-
ment of tumor margin and depth of invasion into the bron-
chial wall using endobronchial ultrasound imaging and opti-
cal coherence tomography may greatly improve the quality
and efficacy of PDT25 (Fig. 1). If the tumor recurs, we
generally perform PDT again. When additional systemic or
local treatment is needed, we administer chemotherapy or
radiation or perform an operation for recurrent lesions.
PDT FOR PERIPHERAL LUNG CANCER
Computed tomography screening for lung cancer has
attracted much attention for its ability to detect peripheral-
type early-stage lung cancer.26,27 Okunaka et al.28 reported
interstitial PDT for peripheral-type lung cancer by placing an
optical fiber inside the tumor using a percutaneous needle. In
their study, nine patients were deemed unsuitable for surgery
or radiotherapy because of poor cardiopulmonary function.
The procedure was carried out with local anesthesia infil-
trated into the chest wall, 48 hours after Photofrin adminis-
tration. Needles containing an internal catheter were inserted
percutaneously under computed tomographic guidance. The
needles were then extracted and a diffuser fiber with a
TABLE 1. Centrally Located Early-Stage Lung Cancers
Treated with PDT
Study Group Photosensitizer
CR Rate, % (No. of CR
Lesions/Total Lesions)
Furuse et al.15 Photofrin 84.8% (50/59)
Cortese et al.19 Photofrin 69.6% (16/23)
Kato et al.18 Laserphyrin 82.9% (33/39)
Furukawa et al.17 Photofrin 92.8% (77/83)
(lesions 1.0 cm in diameter)
CR, complete response.
FIGURE 1. A case of 82-year-old man with primary squa-
mous cell carcinoma. The star indicates the tumor lesion. (A)
Hypertrophic-type squamous cell carcinoma located at the
left upper bronchus. (B) Photodynamic diagnosis using fluo-
rescence bronchoscopy before Laserphyrin PDT. Photody-
namic diagnosis image of area of tumor shows red fluores-
cence. (C) Endobronchial ultrasound imaging shows a small
tumor before Laserphyrin PDT. The tumor appears as an iso-
echoic area and was diagnosed as intracartilaginous. (D)
Three months after Laserphyrin PDT. Complete response was
obtained.
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2-cm-long tip for light delivery was positioned in the tumor
through the catheter. Nine patients were enrolled in this trial,
and none had serious complications. Two patients had pneu-
mothorax, in one of which chest drainage was necessary,
while the other patient recovered spontaneously. Although no
CR was obtained, partial response was achieved in seven
cases. Recently, other treatments for peripheral-type lung
cancer such as radiofrequency ablation and microwave coag-
ulation were reported to be feasible and safe.29,30 However,
these treatments need to be examined further and discussed.
In the future, we need to conduct randomized trials compar-
ing PDT and surgical resection for peripheral lung cancer.
PDT FOR ADVANCED LUNG CANCER WITH
AIRWAY OBSTRUCTION
The majority of patients diagnosed with lung cancer
have advanced disease, and most patients with inoperable
tracheobronchial lesions will require palliative treatment to
open an obstructed airway. Diaz-Jimenez et al.31 reported that
PDT and conventional Nd-YAG laser therapy appeared to be
equally effective and safe in relieving airway obstruction in
advanced lung cancer. An advantage of PDT is the longer
time to treatment failure. PDT was found to achieve a lower
rate of immediate reopening, and it is thought to be unsuitable
when tracheobronchial obstruction requires rapid relief.32–35
Furukawa et al.36 reported that overall effective opening of
bronchi was achieved in 61 of 81 lesions (75%) treated by
PDT, compared with 143 of 177 lesions (81%) treated by
Nd-YAG laser. PDT seemed to be useful for obstruction of
lobar and segmental bronchus.
PREOPERATIVE PDT
For lung cancer patients with low pulmonary function,
it is very important to reduce the extent of lung resection. In
1985, we began using PDT before surgery.37,38 Okunaka et
al.39 reported that preoperative PDT was performed in 32
patients with lung cancer for the purpose of either reducing
the extent of resection or increasing operability. An operation
was performed 3 to 9 weeks after PDT. In their study,
conversion to an operable condition was achieved in four of
five inoperable cases, whereas 23 of 27 patients who were
originally candidates for pneumonectomy were managed with
lobectomy or sleeve lobectomy. They concluded T4 primary
squamous cell carcinoma cases with superficial invasion
extending to the upper lobe bronchus are good candidates for
combination therapy.
NEW APPLICATIONS OF PDT FOR THE
TREATMENT OF LUNG CANCER
It has been reported that PDT induces oxidative stress,
localized inflammation, and vascular injury within treatment
fields, and these responses can lead to increased expression of
angiogenic factors and cytokines. Recently, PDT using Pho-
tofrin increased expression of vascular endothelial growth
factor and prostaglandin E2 in murine tumors.40–42 Ferrario et
al.43 reported that the combination of vascular endothelial
growth factor inhibitors or cyclooxygenase-2 improved the
therapeutic efficacy of PDT. They demonstrated that PDT-
treated tumors have increased expression of matrix metallo-
proteinases and that pharmacologic inhibition of matrix met-
alloproteinases can increase the antitumor effect of PDT in
vivo. In the future, the combination therapies using PDT and
molecule-targeted agents such as vascular endothelial growth
factor inhibitors or matrix metalloproteinase inhibitors may
become treatment options for patients with lung cancer.
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